Cyclosporin A curtails the progression of free light chain synthesis in the CSF of patients with multiple sclerosis. Export

@article{citeulike:2564857, abstract = {Free light chains in the cerebrospinal fluid of patients with multiple sclerosis correlate closely with disease activity. As part of a double-blind placebo controlled trial of immunosuppression using cyclosporin A in patients with multiple sclerosis, light chain analysis was performed on pre- and post-treatment CSF samples in 19 patients, nine having received cyclosporin A and 10 placebo. The placebo treated patients showed continued immunological activity, as evidenced by an increase in both free kappa and lambda chains, but cyclosporin A treatment resulted in no change or an improvement in light chain response, indicative of suppression of continued activity. As cyclosporin A does not enter the CSF, this implies that systemic stimulation is at least partly responsible for continued disease activity in multiple sclerosis. Cyclosporin A may thus be effective in preventing the deterioration of patients with multiple sclerosis.}, address = {Department of Neurochemistry, Institute of Neurology, London, UK.}, author = {McLean, B. N. and Rudge, P. and Thompson, E. J.}, citeulike-article-id = {2564857}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/2500497}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=2500497}, issn = {0022-3050}, journal = {J Neurol Neurosurg Psychiatry}, keywords = {csf, flc, ms}, month = {April}, number = {4}, pages = {529--531}, posted-at = {2008-03-20 05:07:53}, priority = {2}, title = {Cyclosporin A curtails the progression of free light chain synthesis in the CSF of patients with multiple sclerosis.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/2500497}, volume = {52}, year = {1989} }

TY - JOUR ID - citeulike:2564857 L3 - citeulike-article-id:2564857 N2 - Free light chains in the cerebrospinal fluid of patients with multiple sclerosis correlate closely with disease activity. As part of a double-blind placebo controlled trial of immunosuppression using cyclosporin A in patients with multiple sclerosis, light chain analysis was performed on pre- and post-treatment CSF samples in 19 patients, nine having received cyclosporin A and 10 placebo. The placebo treated patients showed continued immunological activity, as evidenced by an increase in both free kappa and lambda chains, but cyclosporin A treatment resulted in no change or an improvement in light chain response, indicative of suppression of continued activity. As cyclosporin A does not enter the CSF, this implies that systemic stimulation is at least partly responsible for continued disease activity in multiple sclerosis. Cyclosporin A may thus be effective in preventing the deterioration of patients with multiple sclerosis. IS - 4 JF - J Neurol Neurosurg Psychiatry SN - 0022-3050 AD - Department of Neurochemistry, Institute of Neurology, London, UK. EP - 531 TI - Cyclosporin A curtails the progression of free light chain synthesis in the CSF of patients with multiple sclerosis. VL - 52 SP - 529 KW - csf KW - flc KW - ms AU - McLean, BN AU - Rudge, P AU - Thompson, EJ PY - 1989/04// UR - http://view.ncbi.nlm.nih.gov/pubmed/2500497 ER -